|
YM BIOSCIENCES INC.
|
|
RSS 
Printer friendly
Subscribe to Portfolio e-mail
 |
| August 10, 2010 |
|
YM BioSciences granted Orphan Drug Designation for CYT387
|
|
7:30 ET
|
| August 5, 2010 |
|
YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
|
|
7:00 ET
|
| June 3, 2010 |
|
YM BioSciences appoints Dr. Nick Glover as President and Chief Operating Officer
|
|
17:00 ET
|
|
YM BioSciences raises US$3.2 million in support of JAK 1/2 program
|
|
7:30 ET
|
| May 27, 2010 |
|
YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
|
|
7:30 ET
|
| May 21, 2010 |
|
YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting
|
|
7:30 ET
|
| May 13, 2010 |
|
YM BioSciences third quarter 2010 operational and financial results
|
|
7:30 ET
|
| April 26, 2010 |
|
YM BioSciences announces controlled equity offering
|
|
17:15 ET
|
| April 19, 2010 |
|
YM BioSciences announces pivotal preclinical efficacy data for the JAK1/2 inhibitor CYT387 published in Blood, the Journal of the American Society of Hematology
|
|
7:30 ET
|
| March 30, 2010 |
|
YM BioSciences announces early expansion of ongoing CYT387 Phase I/II clinical study based on favorable safety and activity data
|
|
7:30 ET
|
|
RSS Printer friendly
Subscribe to Portfolio e-mail
